FY2024 EPS Estimates for Xeris Biopharma Boosted by Analyst

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – Equities researchers at HC Wainwright lifted their FY2024 earnings per share (EPS) estimates for Xeris Biopharma in a note issued to investors on Monday, November 11th. HC Wainwright analyst O. Livnat now forecasts that the company will earn ($0.41) per share for the year, up from their prior estimate of ($0.42). HC Wainwright has a “Buy” rating and a $6.60 price target on the stock. The consensus estimate for Xeris Biopharma’s current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for Xeris Biopharma’s Q4 2024 earnings at ($0.07) EPS, FY2025 earnings at ($0.29) EPS, FY2026 earnings at ($0.03) EPS and FY2028 earnings at $0.51 EPS.

Separately, Piper Sandler downgraded shares of Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price target on the stock. in a research note on Monday.

Xeris Biopharma Stock Down 4.0 %

Shares of Xeris Biopharma stock opened at $3.15 on Wednesday. Xeris Biopharma has a 52 week low of $1.46 and a 52 week high of $3.64. The business’s fifty day simple moving average is $2.98 and its 200-day simple moving average is $2.52.

Hedge Funds Weigh In On Xeris Biopharma

Several institutional investors have recently bought and sold shares of XERS. Simplicity Wealth LLC purchased a new position in shares of Xeris Biopharma in the second quarter valued at approximately $27,000. Wealth Enhancement Advisory Services LLC purchased a new stake in Xeris Biopharma during the 3rd quarter worth approximately $35,000. Bayesian Capital Management LP acquired a new stake in Xeris Biopharma during the 1st quarter worth approximately $37,000. Allspring Global Investments Holdings LLC boosted its position in Xeris Biopharma by 4,512.5% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 16,282 shares of the company’s stock valued at $37,000 after buying an additional 15,929 shares during the period. Finally, Asset Management Group Inc. grew its stake in shares of Xeris Biopharma by 130.7% in the second quarter. Asset Management Group Inc. now owns 26,480 shares of the company’s stock worth $60,000 after acquiring an additional 15,000 shares in the last quarter. 42.75% of the stock is owned by institutional investors and hedge funds.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.